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Abstract
There are different phenotypes of obstructive sleep apnoea (OSA), many of which have not
been characterised. Identification of these different phenotypes is important in defining prog-
nosis and guiding the therapeutic strategy. The aim of this study was to characterise the
entire population of continuous positive airway pressure (CPAP)-treated patients in Catalo-
nia and identify specific patient profiles using cluster analysis.
A total of 72,217 CPAP-treated patients who contacted the Catalan Health System (Cat-
Salut) during the years 2012 and 2013 were included. Six clusters were identified, classified
as “Neoplastic patients” (Cluster 1, 10.4%), “Metabolic syndrome patients” (Cluster 2,
27.7%), “Asthmatic patients” (Cluster 3, 5.8%), “Musculoskeletal and joint disorder patients”
(Cluster 4, 10.3%), “Patients with few comorbidities” (Cluster 5, 35.6%) and “Oldest and car-
diac disease patients” (Cluster 6, 10.2%). Healthcare facility use and mortality were highest
in patients from Cluster 1 and 6. Conversely, patients in Clusters 2 and 4 had low morbidity,
mortality and healthcare resource use.
Our findings highlight the heterogeneity of CPAP-treated patients, and suggest that OSA
is associated with a different prognosis in the clusters identified. These results suggest the
need for a comprehensive and individualised approach to CPAP treatment of OSA.
Introduction
Obstructive sleep apnoea (OSA) is a chronic disorder characterised by recurrent episodes of
upper airway collapse during sleep, and affects 5–14% of adults aged 30–70 years [1]. OSA has
been linked with increased rates of morbidity and mortality due to its strong association with
hypertension, metabolic, cardiovascular and cerebrovascular diseases, and cancer [2,3]. OSA
PLOS ONE | https://doi.org/10.1371/journal.pone.0185191 September 21, 2017 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Turino C, Bertran S, Gavalda´ R, Teixido´ I,
Woehrle H, Rue´ M, et al. (2017) Characterization of
the CPAP-treated patient population in Catalonia.
PLoS ONE 12(9): e0185191. https://doi.org/
10.1371/journal.pone.0185191
Editor: Clemens Heiser, Technische Universitat
Munchen, GERMANY
Received: June 16, 2017
Accepted: September 7, 2017
Published: September 21, 2017
Copyright: © 2017 Turino et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This study was supported by the Spanish
Respiratory Society (SEPAR), Associacio´
Lleidatana de Respiratori (ALLER) and ResMed, a
company that provides diagnostic services and
treatment for sleep apnoea. The funders had no
role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. ResMed paid the salaries of the author
HW, but did not have any additional role in the
has a negative impact on quality of life, increases the risk of traffic accidents and has an impor-
tant socioeconomic impact [4,5]. Given these multiple medical and social consequences, OSA
could be considered a complex and heterogeneous disorder, deserving of a multidisciplinary
approach and personalised treatment. However, there is really only one standard approach to
the management of OSA–the application of nocturnal continuous positive airway pressure
(CPAP) to splint the upper airways open. CPAP has been shown to improve quality of life and
to decrease arterial blood pressure in patients with resistant hypertension [6, 7].
Using distinct types and sources of data, some authors have recently used cluster analysis to
identify different phenotypes of OSA patients [8–11]. Cluster analysis allows patients to be
grouped according to similar characteristics while maximising differences among different
patient groups. Applied to OSA patients, cluster analysis could help to improve knowledge
about the condition, confirm known associations with comorbidities, and potentially identify
currently unknown associations. In Catalonia, approximately 1% of the general population is
currently estimated to be using CPAP. However, there are no clear data on the profiles of OSA
patients treated with CPAP, whether there is heterogeneity within this population, and which
pathologies or comorbidities might be associated with different patient profiles.
This study characterised the entire CPAP-treated population of Catalonia using cluster
analysis in order to define specific profiles based on age, sex, associated comorbidities, mortal-
ity and the use of healthcare resources.
Methods
Design, setting and study population
This cross-sectional study was conducted in Catalonia (Spain) based on data from the Agency
for Health Quality and Assessment of Catalonia (AQuAS). AQuAS is a public entity working
under the auspices of Catalonia’s Health Services Department promoting the quality, safety
and sustainability of the public Catalan healthcare system. All OSA patients in the Catalan
Health Service who were treated with CPAP and had any use of healthcare resources during
2012 and/or 2013 were included in the analysis. Patients receiving CPAP via private health ser-
vices were excluded because full data were not available. Since all data were anonymised, nei-
ther individual patient consent nor ethical approval were required.
Coding and selection of diseases
The International Classification of Disease version 9 (ICD-9) was used for disease coding at
each contact with the Catalan Public Health Service (in primary care, hospital or nursing
home).
For this study, we selected a combination of the most frequent diagnoses in our dataset and
made a list of the most clinically relevant diagnoses (Table 1) [9]. Several diagnoses were
grouped in disease categories in order to facilitate information management. To obtain consis-
tent and clinically relevant patterns of association, and to avoid spurious relationships that
could bias the results, we considered only diagnoses with a prevalence of> 1%.
Statistical analysis
Descriptive statistics of mean (standard deviation) or median [interquartile range (IQR)] were
estimated for quantitative variables with a normal or non-normal distribution, respectively,
while absolute and relative frequencies were used for qualitative variables. Normal distribution
was analysed using the Shapiro-Wilks test.
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Table 1. The most frequent and clinical relevant diagnoses.
Comorbidities CHARS ICD-9 Diagnosis Code(s)
HIV 042.xx HIV
Malignant neoplasms 140.xx—149.xx Lip, oral cavity and pharynx
150.xx—159.xx Digestive organs and peritoneum
160.xx—165.xx Respiratory and intrathoracic organs
170.xx—176.xx Bone, connective tissue, skin and breast
179.xx—189.xx Genitourinary organs
190.xx—199.xx Other locations
200.xx—208.xx Lymphatic tissues and hematopoietic
Diabetes 250.xx Diabetes mellitus
Dyslipidaemia 272.xx Disorders of lipid metabolism
Obesity 278.xx Overweight, obesity and other types of hyperalimentation
Anaemia 280.xx Anaemia due to iron deficiency
281.xx Other deficiency anaemia
282.xx Hereditary haemolytic anaemias
283.xx Acquired haemolytic anaemias
284.xx Aplastic anaemia and other medullary insufficiency syndromes
285.xx Other anaemias and unspecified anaemias
Dementia 290.xx Dementia
Schizophrenic disorders 295.xx Schizophrenic disorders
Mental disorders 296.xx Mood (affective) disorder
305.xx Drugs without dependence
Anxiety 300.xx Anxiety, dissociative and somatoform disorders
Parkinson’s disease 332.xx Parkinson’s disease
Hypertension 401.xx Essential hypertension
402.xx Hypertensive heart disease
403.xx Chronic hypertensive kidney disease
404.xx Hypertensive chronic heart and kidney disease
405.xx Secondary hypertension
Other heart diseases 414.xx Other forms of chronic ischemic heart disease
Dysrhythmia 427.xx Dysrhythmia
Heart failure 428.xx Heart failure
Cerebrovascular
diseases
430.xx Subarachnoid haemorrhage
431.xx Intracerebral haemorrhage
432.xx Other intracranial haemorrhage and not specified intracranial
haemorrhage
433.xx Stenosis and occlusion of precerebral arteries
434.xx Occlusion of the brain arteries
435.xx Transient cerebral ischemia.
436.xx Poorly-defined acute cerebrovascular disease
437.xx Other cerebrovascular diseases and other poorly-defined
cerebrovascular diseases
438.xx Late effects of cerebrovascular disease
COPD 490.xx Non specified as acute or chronic bronchitis
491.xx Chronic bronchitis
492.xx Emphysema
Asthma 493.xx Asthma
Bronchiectasis 494.xx Bronchiectasis
Pancreatic diseases 577.xx Pancreatic diseases
(Continued )
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A Multiple Correspondence Analysis (MCA) was used to reduce dimensionality on the
studied diagnoses. The number of dimensions obtained by MCA was identified using the Kai-
ser’s criterion and the Scree test. The individual coordinates obtained with MCA were intro-
duced in a k-means cluster analysis. Cluster analysis has been used to describe homogeneous
subgroups (clusters) with similar characteristics (intra-cluster distance minimised), but differ-
ent from other groups (inter-cluster distance maximised). The final number of clusters was
defined on the basis of maximising the ratio between intra-cluster and inter-cluster variance,
more specifically Calinsky-Harabasz’s criterion. The R statistical software, version 3.3.1, was
used for all the analyses.
Results
Patient characteristics
Of the 7,478,968 population in Catalonia (2013), 71,217 patients (0.95%) were being treated
with CPAP; 70,469 of these used healthcare services (2012–2013) and were included in the
analysis (Fig 1). Median age was 64.5 years [IQR57.0; 72.0], 74.9% were men, and 5.29% died
during the study period. Median time on CPAP was 34.9 months [IQR 14.8; 58.5]. The most
frequent diagnoses were hypertension (61.2%), dyslipidaemia (29.9%), diabetes (29.6%) and
obesity (18.3%).
Cluster analysis
Six clusters of CPAP-treated OSA patients were identified. Hypertension and diabetes were
present in almost all the clusters among the most frequent comorbidities (Fig 2). The main
characteristics of each cluster are summarized in Table 2.
Cluster 1 (Neoplastic patients) included 7,340 patients (10.4%), a high proportion of whom
had malignant neoplasm (88.5%), and the mortality rate was high (15.0%). Cluster 2 (Meta-
bolic syndrome patients) included 19,535 patients (27.7%). High proportions of patients in
this group had hypertension (84.1%), dyslipidaemia (57.1%), obesity (35.9%) and diabetes
(53.9%); mortality was low (1.9%). Cluster 3 (Asthmatic patients) included 4,082 patients
(5.8%). This cluster of patients all had asthma, included a high proportion of women (53.0%)
and had a low mortality rate (4.8%). Cluster 4 (Musculoskeletal and joint disorders patients)
Table 1. (Continued)
Comorbidities CHARS ICD-9 Diagnosis Code(s)
Chronic renal failure 584.xx Chronic renal failure
Chronic nephropathy 585.xx Chronic nephropathy
Prostatic hyperplasia 600.xx Prostatic hyperplasia
Inflammatory arthritis 714.xx Inflammatory arthritis
Osteoarthrosis 715.xx Osteoarthrosis and related disorders
Other joint disorders 719.xx Other joint disorders and unspecified joint disorders
Back disorders 724.xx Other disorders and unspecified back disorders
Musculoskeletal
disorders
726.xx Peripheral tendinitis
Joint disorders 729.xx Other soft tissue disorders
Osteoporosis 733.xx Osteoporosis
List of the diagnoses and group of diagnoses used to perform the Multiple Correspondence Analysis (MCA)
and the cluster analysis.
https://doi.org/10.1371/journal.pone.0185191.t001
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Fig 1. Sampling framework. Abbreviations: OSA, obstructive sleep apnoea; CPAP, continuous positive airway pressure.
https://doi.org/10.1371/journal.pone.0185191.g001
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included 7,234 patients (10.3%), who had peripheral tendinitis (58.2%), joint diseases (15.2%)
and muscular disease (51.0%); this group had the lowest mortality rate (1.4%). Cluster 5
(Patients with few comorbidities) grouped the patients with few comorbidities (n = 25,088
patients, 35.6%). Use of healthcare resources by this group was low, as was the mortality rate
(3.6%). Cluster 6 (Oldest and cardiac disease patients, n = 7,190, 10.2%) had a median age of
72.0 years [IQR 64.5;79.5], and patients had dysrhythmia (67.5%) and heart failure (57.1%).
This group had one of the highest mortality rates (14.6%).
Mortality rates in both Cluster 1 and 6 were high, but the patient groups differed with
respect to the primary comorbidity diagnosis and healthcare resource use. Specifically, patients
in Cluster 6 used a wide range of healthcare resources whereas those in Cluster 1 had more
hospital and nursing home visits (Fig 3). Mortality rates in Cluster 2 and 4 were also had simi-
lar (low), but patients in Cluster 4 used more primary care resources than those in Cluster 2.
In addition, mortality rates were similar in Clusters 3 and 5, but healthcare resource use was
again different, being very low for Cluster 5 and higher for Cluster 3.
Fig 2. The proportion of each comorbidity in each cluster. Cluster 1: Neoplastic patients. Cluster 2: Metabolic syndrome patients.
Cluster 3: Asthmatic patients. Cluster 4: Musculoskeletal and joint disorders patients. Cluster 5: Patients with few comorbidities. Cluster 6:
Oldest and cardiac disease patients. Abbreviations: DLP, dyslipidaemia; OB, obesity; BD, back disorders; OA, osteoarthrosis; HF, heart
failure; CD, cardiac dysrhythmia; ADT, addiction; ANXTY, anxiety; OHD, other heart disease; OJD, other joint disease; PT, peripheral
tendinitis; CKD, chronic kidney disease; ASTH, asthma; STD, soft tissue disease; MN, malignant neoplasm; HBP, hypertension; CVD,
cerebrovascular; COPD, chronic obstructive pulmonary disease; ANM, anaemia; DM, diabetes mellitus; OP, osteoporosis.
https://doi.org/10.1371/journal.pone.0185191.g002
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Discussion
This study is the first cluster analysis involving the entire CPAP-treated population with OSA
of Catalonia. Using data from the Catalan Health System, we defined a general profile of OSA
patients treated with CPAP, largely characterised by middle-aged men, with a high prevalence
of hypertension, dyslipidaemia, diabetes and obesity. At the same time, cluster analysis identi-
fied six patient groups that showed different patterns of comorbidities, mortality, and health-
care resource use.
Similar to previous literature, we found that hypertension, diabetes and dyslipidaemia were
highly prevalent among OSA patients [12–15]. In a sample of more than 18,000 patients from
a prospective national registry, Bailey et al. also confirmed the high burden of comorbidities in
OSA patients, identifying six clusters [8]. However, similar to other previous cluster studies,
they characterised OSA patients using data from a national registry, clinical practice and sleep
registry analysis [8–11], while we exclusively used the coded diseases and discharge data from
hospitals, nursing homes and primary care institutions, the number of visits to the emergency
room or primary care, and medication use. The observation of a cluster comprised entirely of
patients with asthma, mostly women, confirmed previous observations of an OSA-asthma
overlap syndrome [16] and suggests a need for more specific studies in this field. Asthma is, in
fact, a recognised risk factor for developing OSA [17] and women with OSA are more likely to
be diagnosed with asthma [18].
Table 2. Patient demographic characteristics and annual proportion of health care resource use for the entire cohort and by cluster.
All clusters Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 p value
N = 70,469 N = 7,340 N = 19,535 N = 4,082 N = 7,234 N = 25,088 N = 7,190
Gender (male) 52805 (74.9%) 5742 (78.2%) 15285 (78.2%) 1917 (47.0%) 4617 (63.8%) 20139 (80.3%) 5105 (71.0%) <0.001
Age (years) 64.5 [57.0;72.0] 69.5 [62.0;77.0] 64.5 [57.0;69.5] 67.0 [57.0;74.5] 62.0 [57.0;69.5] 62.0 [52.0;67.0] 72.0 [64.5;79.5] <0.001
CPAP time (months) 34.9 [14.8;58.5] 38.5 [17.9;63.6] 36.8 [15.4;60.8] 32.8 [12.8;55.5] 33.5 [13.7;57.2] 34.2 [14.8;57.4] 32.1 [13.3;56.6] <0.001
Mortality 3726 (5.29%) 1103 (15.0%) 364 (1.86%) 198 (4.85%) 102 (1.41%) 906 (3.61%) 1053 (14.6%) <0.001
Nurse home (0 visits) 69084 (98.0%) 6974 (95.0%) 19368 (99.1%) 3949 (96.7%) 7161 (99.0%) 24882 (99.2%) 6750 (93.9%) <0.001
Nurse home (>0
visits)
1385 (1.97%) 366 (4.99%) 167 (0.85%) 133 (3.26%) 73 (1.01%) 206 (0.82%) 440 (6.12%)
Hospital (0 visits) 46183 (65.5%) 3335 (45.4%) 14144 (72.4%) 2362 (57.9%) 4768 (65.9%) 18722 (74.6%) 2852 (39.7%) <0.001
Hospital (1 visit) 13510 (19.2%) 1812 (24.7%) 3407 (17.4%) 841 (20.6%) 1560 (21.6%) 4231 (16.9%) 1659 (23.1%)
Hospital (>1 visit) 10776 (15.3%) 2193 (29.9%) 1984 (10.2%) 879 (21.5%) 906 (12.5%) 2135 (8.51%) 2679 (37.3%)
Primary care (0–2.5
visits)
19382 (27.5%) 1410 (19.2%) 3782 (19.4%) 667 (16.3%) 920 (12.7%) 11896 (47.4%) 707 (9.83%) <0.001
Primary care (2.5–5
visits)
17660 (25.1%) 1721 (23.4%) 5703 (29.2%) 882 (21.6%) 1735 (24.0%) 6679 (26.6%) 940 (13.1%)
Primary care (>5
visits)
33427 (47.4%) 4209 (57.3%) 10050 (51.4%) 2533 (62.1%) 4579 (63.3%) 6513 (26.0%) 5543 (77.1%)
Pharmacy (0–1.5
drugs)
24893 (35.3%) 1916 (26.1%) 5251 (26.9%) 916 (22.4%) 2004 (27.7%) 13873 (55.3%) 933 (13.0%) <0.001
Pharmacy (1.5–3.5
drugs)
22919 (32.5%) 2264 (30.8%) 7879 (40.3%) 1148 (28.1%) 2620 (36.2%) 7336 (29.2%) 1672 (23.3%)
Pharmacy (>3.5
drugs)
22657 (32.2%) 3160 (43.1%) 6405 (32.8%) 2018 (49.4%) 2610 (36.1%) 3879 (15.5%) 4585 (63.8%)
Data are presented as median [interquartile range; IQR] and n (%).
Cluster 1: Neoplastic patients. Cluster 2: Metabolic syndrome patients. Cluster 3: Asthmatic patients. Cluster 4: Musculoskeletal and joint disorders
patients. Cluster 5: Patients with few-comorbidities. Cluster 6: Oldest and cardiac disease patients.
https://doi.org/10.1371/journal.pone.0185191.t002
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Over and above the characterisation of six clusters, the CPAP-treated population from Cata-
lonia could be divided into two major groups. Almost 20% of the overall population were allo-
cated to clusters 1 and 6, and showed the most advanced age and the highest mortality. The
majority of patients (88.5%) in Cluster 1 (Neoplastic patients) had a malignant neoplasm, most
frequently of genitourinary or gastrointestinal origin. This is of interest given some current lit-
erature reports of a higher prevalence of cancer (particularly pancreatic or renal tumours) in
patients with OSA [19]. Cluster 6 (Oldest and cardiac patients) included the oldest individuals
(median age 72.0 years), with the highest prevalence of cardiac failure and cardiac arrhythmias.
Patients in Clusters 1 and 6 showed the highest mortality and rate of hospitalisation, almost cer-
tainly due to the underlying comorbidities rather than as a result of OSA. The presence of car-
diovascular diseases has been associated with a worse prognosis in patients using CPAP [20]
and CPAP treatment of sleep apnoea has not been shown to improve survival in patients with
these comorbidities [21]. Furthermore, in patients over 65 years of age, the presence of OSA
seems to have only a slight impact on quality of life, which is determined to a greater extent by
the presence of comorbidities [22]. In contrast, more than a half of our population was male,
Fig 3. Percentages of high use of health care resources per year in each cluster. Cluster 1: Neoplastic
patients. Cluster 2: Metabolic syndrome patients. Cluster 3: Asthmatic patients. Cluster 4: Musculoskeletal
and joint disorders patients. Cluster 5: Patients with few comorbidities. Cluster 6: Oldest and cardiac disease
patients. (% Mortality).
https://doi.org/10.1371/journal.pone.0185191.g003
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had few comorbidities, and low mortality and healthcare resource use (Clusters 2 and 5). In
these groups, OSA appears to be the most important determinant of patient prognosis [23], and
patients with these characteristics could be more likely to benefit from CPAP treatment.
Given the different phenotypes identified, the results of our study could have an important
impact on Catalan health policies. The Catalan Health System provides free healthcare services
to more than 7 million people [24] with annual spending of around €8,000 million [25]. CPAP
treatment is provided at no cost to approximately 70,000 people, and cost effectiveness is only
achieved after the second year of treatment and exclusively in patients who are compliance
with therapy [26]. In Catalonia CPAP therapy is typically prescribed to patients with severe
OSA or for more mild disease that is accompanied by daytime hypersomnolence or other
symptoms attributable to OSA. Daily CPAP compliance is closely monitored because CPAP
treatment is completely free of charge only for patients who used their device for more than
3 hours per night; if this is not the case, CPAP is withdrawn [27]. Even in the absence of spe-
cific data about the compliance of our population, it would be reasonable to assume device
usage of at least 3 h/night given the treatment criteria and the fact that median duration of
CPAP use was 34 months.
Understanding inter-patient differences in clinical presentations of OSA could facilitate
more efficient resource management and provision of care. In the light of cluster analysis
results, one-third of all CPAP-treated OSA patients in Catalonia (Clusters 1 & 6) are in fact
receiving a treatment that probably will not markedly influence their life expectancy or quality
of life. Medical resources could be better spent for the remaining population of patients with
few comorbidities, for whom a clinical benefit of CPAP treatment would be expected.
This study has several strengths, including the large and comprehensive study population
and the statistical method used. In addition, data about patient characteristics, comorbidities
and resource use were provided by AQuAS, ensuring high quality information. Furthermore,
data were collected from different public health settings (primary care, nursing homes and
hospitals) increasing the generalisability of our findings. However, there are some limitations
to be considered. Firstly, the absence of clinical information about the study population (e.g.
symptoms, quality of life, sleep records, CPAP compliance) limits the ability to fully character-
ise each cluster. Secondly, use of the ICD-9 classification system reduces the specificity of dis-
ease definitions. The ICD-9 sometimes groups similar diseases together, reducing the ability to
differentiate between them. However, it does ensure the homogeneity and accuracy of the dis-
ease classification. Finally, the absence of a control group also limits our capacity to define
clusters and assess whether the features identified are specific to OSA patients.
Conclusions
This study used cluster analysis based on diagnostic profile to characterise the entire CPAP-
treated population of Catalonia for the first time. Six clusters were identified, but the majority
of patients could be distributed into two broad groups: one older with high mortality and
healthcare resource use, and the other with few comorbidities, low mortality and lower health-
care resource use. Our study highlights the heterogeneity of OSA patients on CPAP treatment,
emphasises the importance of identifying the indication and expected benefits of CPAP in spe-
cific OSA phenotypes, and offers the opportunity to tailor interventions for specific patient
groups.
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